Alvion Pharmaceuticals has signed an out-licensing agreement with Austell Pharmaceuticals to market a leading cardiovascular product in South Africa. The product is an added value medicine offering tremendous advantages to patients. Austell and Alvion plan to launch the product in 2023, as a daily prescription treatment, offering a unique therapy to the South African people.

John Bouros, CEO of Alvion Pharmaceuticals, said: “Alvion Pharmaceuticals is delighted to enter into agreement with Austell Pharmaceuticals offering an important proprietary and looks forward to launching the product in African region. The product is already launched in most of the European markets, and we expect to be among the leading companies in such type of therapies the years to come. We intend to further develop this collaboration with Austell Pharmaceuticals in more products, focusing on cardiovascular therapeutic categories and offering high quality medicines to the region.”